Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders

Inclusion Criteria: * Men and women over 60 years of age. * DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes. * Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28. * Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both * Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool. * Having voluntarily and informedly agreed to participate in the study (signed written consent). * Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool). * Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access. * Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group. * Subjects covered by a social security scheme. Exclusion Criteria: * Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD. * Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder). * Major hearing or visual impairments. * History of premorbid intellectual disability. * Patients under guardianship, conservatorship, or legal protection. * Patients who have already used the Lilia app * Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study. * Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.